AN2 Therapeutics to Present at Jefferies Healthcare Conference
25 Maio 2023 - 5:10PM
Business Wire
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage
biopharmaceutical company focused on developing treatments for
rare, chronic, and serious infectious diseases with high unmet
needs, today announced that Eric Easom, Co-Founder, President and
CEO, will present at the Jefferies Healthcare Conference.
Details of the event are as follows:
Jefferies Healthcare Conference, June 7-9, 2023 in New York,
NY.
- Eric Easom, Co-Founder, President and CEO, will provide a
corporate overview on Thursday, June 8, at 4:30 p.m. ET.
A webcast of the presentation can be accessed on the Investors
section of the AN2 Therapeutics website at www.an2therapeutics.com.
An archived replay will be available for at least 30 days following
the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing treatments for rare, chronic, and serious
infectious diseases with high unmet needs. Our initial candidate is
epetraborole, which we are studying as a once-daily, oral treatment
with a novel mechanism of action for patients with nontuberculous
mycobacteria (NTM) lung disease, a rare, chronic, and progressive
infectious disease caused by bacteria known as mycobacteria that
leads to irreversible lung damage and can be fatal. For more
information, please visit our website at
www.an2therapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230525005314/en/
COMPANY CONTACT: Lucy O. Day Chief Financial Officer
l.day@an2therapeutics.com
INVESTOR AND MEDIA CONTACT: Anne Bowdidge
ir@an2therapeutics.com
AN2 Therapeutics (NASDAQ:ANTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AN2 Therapeutics (NASDAQ:ANTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024